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Abstract 
Hepatocellular carcinoma (HCC) causes high mortality worldwide with 50 per cent of 
them in China. HCC cases are as a result of a viral hepatitis (hepatitis B or hepatitis C), 
metabolic toxins such as alcohol or aflatoxin, conditions like hemochromatosis and 
alpha 1-antitrypsin deficiency or non-alcoholic steatohepatitis (NASH). The high 
prevalence rate of hepatitis C virus (HCV occurs in African and Asian countries. The 
markers of hepatitis C infection (positive-anti HCV) are found in 80% - 90% patients in 
Japan, 70% in Egypt, 40- 50% in Pakistan and 35-40% in Saudi Arabia. China is 
classified as high endemic area with 8% - 20 % prevalence of hepatitis B virus (HBV). 
Other Asian countries are characterized as moderate to high prevalence rate of HBV in 
their population. The prevalence of HBV infection in children has declined in countries 
since the beginning of the vaccination. Chronic infections of hepatitis B and/or C can aid 
the development of HCC by repeatedly causing body’s immune system to attack the 
liver cells, some of which are infected by the virus. Aflatoxin is a carcinogen and aids 
carcinogenesis of HCC in the liver. Ultrasound and imaging modalities are used to aid in 
the diagnosis. Therapies include surgical resection, interventional radiology, and liver 
transplant. Prognosis for metastatic or unresectable HCC has improved due to sorafenib 
(Nexavar ®). Prevention of hepatitis B or C infection, childhood vaccination, reduce 
alcohol intake and avoiding the risk factors is the key to prevent HCC. 
